Taiga Wakabayashi1, Taizo Hibi1,2, Godai Yoneda3, Yasuhito Iwao4, Yu Sawada5, Hiroyuki Hoshino6, Shuichiro Uemura3, Daisuke Ban4, Atsushi Kudo4, Yusuke Takemura1, Kohei Mishima1, Masahiro Shinoda1, Osamu Itano1,7, Takehito Otsubo6, Itaru Endo5, Yuko Kitagawa1, Minoru Tanabe4, Hiroto Egawa3, Masakazu Yamamoto3. 1. Department of Surgery, Keio University School of Medicine, Tokyo, Japan. 2. Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan. 3. Department of Surgery, Tokyo Women's Medical University, Tokyo, Japan. 4. Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan. 5. Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Kanagawa, Japan. 6. Department of Gastroenterological and General Surgery, St. Marianna University School of Medicine, Kanagawa, Japan. 7. Department of Gastrointestinal Surgery, International University of Health and Welfare, Chiba, Japan.
Abstract
BACKGROUND: Survival benefit of liver resection for noncolorectal liver metastases (NCRLM) remains to be defined. METHODS: This multicenter, retrospective cohort analysis included consecutive patients with NCRLM whose primary tumor and all metastases were treated with curative intent between 2000 and 2013. The primary endpoint was 5-year overall survival. Clinicopathological factors that affected prognoses were identified using multivariate Cox regression analyses and were included in a predictive model. RESULTS: Data for 205 patients were analyzed. The three most common primary tumor sites were stomach (39%), pancreas (13%), and urinary tract (10%), with adenocarcinomas the main pathology (52%). R0 resection was achieved in 85%, and the overall survival at 5 years was 41%. In the multivariate analysis, synchronous liver metastases, R1/2 resection, and adenocarcinomas and other carcinomas (with gastrointestinal stromal tumors, neuroendocrine tumors G1/G2, and sarcomas set as the reference group) were independent negative indicators of overall survival. A predictive model effectively stratified the NCRLM patients into low-, intermediate-, and high-risk groups with overall 5-year survival rates of 63%, 38%, and 21%, respectively (P < 0.001). CONCLUSIONS: Patients who underwent curative resection for metachronous disease and favorable tumor pathology are expected to have better survival in the NCRLM cohort.
BACKGROUND: Survival benefit of liver resection for noncolorectal liver metastases (NCRLM) remains to be defined. METHODS: This multicenter, retrospective cohort analysis included consecutive patients with NCRLM whose primary tumor and all metastases were treated with curative intent between 2000 and 2013. The primary endpoint was 5-year overall survival. Clinicopathological factors that affected prognoses were identified using multivariate Cox regression analyses and were included in a predictive model. RESULTS: Data for 205 patients were analyzed. The three most common primary tumor sites were stomach (39%), pancreas (13%), and urinary tract (10%), with adenocarcinomas the main pathology (52%). R0 resection was achieved in 85%, and the overall survival at 5 years was 41%. In the multivariate analysis, synchronous liver metastases, R1/2 resection, and adenocarcinomas and other carcinomas (with gastrointestinal stromal tumors, neuroendocrine tumors G1/G2, and sarcomas set as the reference group) were independent negative indicators of overall survival. A predictive model effectively stratified the NCRLM patients into low-, intermediate-, and high-risk groups with overall 5-year survival rates of 63%, 38%, and 21%, respectively (P < 0.001). CONCLUSIONS:Patients who underwent curative resection for metachronous disease and favorable tumor pathology are expected to have better survival in the NCRLM cohort.
Authors: Muhammad Atiq; Ahmed Siddique Ammar; Rabia Mahmood Ali; Siraj Haider; Imran Ahmed; Faisal Saud Dar Journal: Int J Surg Case Rep Date: 2022-09-14
Authors: Shadi Katou; Franziska Schmid; Carolina Silveira; Lina Schäfer; Tizian Naim; Felix Becker; Sonia Radunz; Mazen A Juratli; Leon Louis Seifert; Hauke Heinzow; Benjamin Struecker; Andreas Pascher; M Haluk Morgul Journal: J Clin Med Date: 2022-03-29 Impact factor: 4.241